BIOMARIN

Serial Number 78738394
Registration 3192347
800

Registration Progress

Application Filed
Oct 21, 2005
Under Examination
Approved for Publication
Sep 27, 2006
Published for Opposition
Oct 17, 2006
Registered
Jan 2, 2007

Trademark Image

BIOMARIN

Basic Information

Serial Number
78738394
Registration Number
3192347
Filing Date
October 21, 2005
Registration Date
January 2, 2007
Published for Opposition
October 17, 2006
Renewal Date
January 2, 2017
Drawing Code
3000

Status Summary

Current Status
Active
Status Code
800
Status Date
Apr 26, 2016
Registration
Registered
Classes
001 005

Rights Holder

BioMarin Pharmaceutical Inc.

03
Address
105 Digital Drive
Novato, CA 94949

Ownership History

BioMarin Pharmaceutical Inc.

Original Applicant
03
Novato, CA

BioMarin Pharmaceutical Inc.

Owner at Publication
03
Novato, CA

BioMarin Pharmaceutical Inc.

Original Registrant
03
Novato, CA

Legal Representation

Attorney
Gregory J. Chinlund

USPTO Deadlines

Next Deadline
535 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2007-01-02)
Due Date
January 02, 2027
Grace Period Ends
July 02, 2027

Application History

26 events
Date Code Type Description Documents
Apr 26, 2016 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Apr 26, 2016 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED Loading...
Apr 26, 2016 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) Loading...
Apr 26, 2016 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED Loading...
Feb 17, 2016 E89R I TEAS SECTION 8 & 9 RECEIVED Loading...
Jan 2, 2016 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED Loading...
Nov 30, 2012 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Nov 30, 2012 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Nov 29, 2012 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Nov 2, 2012 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Jan 2, 2007 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Oct 17, 2006 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 27, 2006 NPUB O NOTICE OF PUBLICATION Loading...
Aug 23, 2006 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Aug 18, 2006 ALIE A ASSIGNED TO LIE Loading...
Aug 11, 2006 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Aug 11, 2006 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Aug 11, 2006 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Aug 11, 2006 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 31, 2006 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 12, 2006 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 12, 2006 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 2, 2006 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 2, 2006 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 25, 2006 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 25, 2005 NWAP I NEW APPLICATION ENTERED IN TRAM Loading...

Detailed Classifications

Class 001
[ Assays and diagnostic screening kits composed primarily of reagents for scientific analysis and research for diagnosis of disorders and physiological processes and for measurement of disease markers for scientific purposes ]
First Use Anywhere: Nov 30, 2004
First Use in Commerce: Nov 30, 2004
Class 005
Pharmaceutical preparations for use in enzyme therapy; pharmaceutical preparations for use in treatment of genetic disorders; [ pharmaceutical preparations for use in burn and wound debridement or cleaning; pharmaceuticals for treatment of inflammation, infectious diseases and cardiovascular diseases; ] assays and diagnostic screening kits composed primarily of reagents for clinical and medical use for analysis and diagnosis of disorders and physiological processes and for measurement of disease markers for medical purposes; carbohydrate inhibiting enzymes for use in disease treatment; [ fungal lytic enzymes for the treatment of fungal infections; ] pharmaceuticals for treatment of lysosomal storage diseases; pharmaceuticals for treatment of mucopolysaccharidoses; pharmaceuticals for treatment of carbohydrate-inhibiting enzyme disorders; [ proteins and enzymes for the production, purification and isolation of biologics for use in the treatment of medical conditions; ] biologics produced by recombinant DNA technology for use in the treatment of pathological medical conditions
First Use Anywhere: Jun 8, 2005
First Use in Commerce: Jun 8, 2005

Additional Information

Design Mark
The mark consists of the word BIOMARIN with the letter "I" consisting of DNA fragments. The mark is not in color.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
001 005